Skip to main content
OpenTrials
Completed

NCT Number: NCT02242370

Effectiveness of MICARDIS® (Telmisartan) on Blood Pressure Control and Quality of Live in Patients With Essential Hypertension

Study to assess the effect of Telmisartan on diastolic and systolic blood pressure and to establish the effect on patient's quality of life scores.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypertension Cardiovascular Diseases Vascular Diseases

Age range

20 year–93 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with Stage I essential Hypertension (diastolic blood pressure 90-99 mmHg, and/or systolic blood pressure 140-159 mmHg)
  • Signed informed consent form

Exclusion criteria

  • Females of childbearing potential

Treatment and study plan

Low dose of telmisartan

Drug

High dose of telmisartan

Drug

Primary outcomes

  1. Change in diastolic blood pressure

    Time frame: Pre-dose, up to 6 weeks after start of treatment

  2. Change in systolic blood pressure

    Time frame: Pre-dose, up to 6 weeks after start of treatment

  3. Changes from baseline in the quality of life (QOL) scores by patient self-assessment

    Time frame: Pre-dose, 6 weeks after start of treatment

Secondary outcomes

  1. Assessment of blood pressure control rate

    Time frame: Up to 6 weeks after start of treatment

  2. Assessment of systolic blood pressure response rate

    Time frame: Up to 6 weeks after start of treatment

  3. Assessment of diastolic blood pressure response rate

    Time frame: Up to 6 weeks after start of treatment

  4. Change from baseline in pulse pressure

    Time frame: Pre-dose, up to 6 weeks after start of treatment

  5. Number of patients with adverse events

    Time frame: Up to 6 weeks

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Official study title

An Open-label Evaluation of the Effectiveness of MICARDIS® (Telmisartan) on Blood Pressure Control and Quality of Life in Patients With Essential Hypertension The MICARDIS COMMUNITY ACCESS TRIAL (MicCAT)

Acronym: MicCAT

Important dates

Study start
1999
Primary completion
2000
First posted
Sep 17, 2014
Registry last updated
Sep 17, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.